Form 4: Akari Therapeutics Director Reports Significant Share Acquisition Following Merger

Akari Therapeutics director, Samir Rashmikant Patel, reports acquiring a substantial number of ordinary shares following the merger with Peak Bio.

Summary

• Samir Rashmikant Patel, a director at Akari Therapeutics, has reported a significant acquisition of ordinary shares.
• The acquisition is a result of the merger between Akari Therapeutics and Peak Bio, which became effective on November 14, 2024.
• Patel acquired 1,404,622,000 ordinary shares through the conversion of Peak Bio shares at an exchange ratio of 0.2935 ADSs per Peak Share.
• Additionally, Patel indirectly owns 4,816,117,500 ordinary shares through PranaBio Investments LLC.
• Patel also directly owns 91,396,000 ordinary shares.
• The ordinary shares may be represented by American Depositary Shares (ADSs), with each ADS currently representing 2,000 ordinary shares.

Sentiment

Score: 7

Explanation: The document reflects a standard corporate action (merger) and subsequent share acquisition by a director. It is a neutral event with no immediate negative or positive implications for the company's performance. The sentiment is therefore moderately positive due to the completion of the merger.

Positives

• The merger with Peak Bio has resulted in a significant increase in share ownership for the director, Samir Rashmikant Patel.
• The transaction was completed as per the terms of the merger agreement.

Industry Context

This filing reflects a significant corporate event, the merger of Akari Therapeutics and Peak Bio, which is a common strategy in the biotech industry to consolidate resources and pipelines. The share acquisition by a director is a typical outcome of such mergers.

Comparison to Industry Standards

• Mergers and acquisitions are a common occurrence in the biotech industry, often leading to changes in share ownership.
• The exchange ratio of 0.2935 ADSs per Peak Bio share is specific to this transaction and would need to be compared to other similar biotech mergers to assess its fairness.
• The level of share ownership by the director is not unusual for a company undergoing a merger, but the specific amount would need to be compared to other similar companies to assess its significance.

Stakeholder Impact

• Shareholders will see a change in the ownership structure of the company due to the merger and subsequent share acquisition.
• The merger may have implications for employees of both Akari Therapeutics and Peak Bio, though this is not detailed in this document.
• The merger may impact the company's future strategic direction and product pipeline.

Key Dates

Keywords

Akari Therapeutics, Merger, Share Acquisition, Form 4, Director, Peak Bio, Ordinary Shares, ADS, Beneficial Ownership